Kara L. Watts

Submitted by Anonymous (not verified) on
Kara L. Watts
https://assets.montefioreeinstein.org/profiles/images/Watts_Kara_MD_2x.jpg
Provider
Faculty
First Name
Kara
Last Name
Watts
NPI
1215222856
Faculty ID
15490
Clinical Terms
Employment Status
part-time
Patient Type
Adult
Department
einstein-dept-urology
einstein-dept-radiology
Gender
Female
Email
kwatts@montefiore.org
Phone
718-920-4531
Titles
Type
Academic
Department
Department of Urology
Department Link
Rank
Associate Professor
Type
Academic
Department
Department of Radiology
Rank
Associate Professor
Tags
me-patientcare-cancer-research-epidemiology
Type
Clinical
Title
Director of Quality Assurance and Improvement, Urology
Tags
me-patientcare-urology-urologiconcology
me-patientcare-urology-general
Type
Clinical
Title
Attending Physician
Type
Clinical
Title
Director, Prostate Screening Program, Montefiore Einstein
Type
Clinical
Title
Associate Professor, Urology
Type
Administrative
Locations
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84154 40.84612)
Address Line 1
1250 Waters place
City
Bronx
State
NY
Zip
10461-2720
Location Title
Montefiore at 1250 Waters Place
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.839137 40.8526781)
Building
Tower 1
Address Line 1
Montefiore Medical Center
Address Line 3
1250 Waters Place
City
Bronx
State
NY
Zip
10461
Location Title
Montefiore Medical Center
Education and Trainings
Education Type Label
Medical Education
Education Institution
University of Connecticut School of Medicine
Education Type Label
Residency
Education Institution
Montefiore Medical Center
CHAM Provider
Off
Professional Title
M.D.
Clinical Focus

Clinical practice focuses on BPH, endourology, and prostate cancer detection and ablation.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Work on quality improvement in healthcare and active surveillance and focal ablation in prostate cancer.<quillbot-extension-portal></quillbot-extension-portal>

EMR ID
56078
Biography

<p>Dr. Kara L. Watts, Associate Professor of Urology, joined the urology faculty at Montefiore in 2016. She completed a fellowship in Quality and Performance Improvement in Healthcare and an extended observership in focal ablation for prostate cancer in the UK. She serves as the Director of Quality Assurance and Improvement for the Department of Urology and leads the prostate cancer screening program.</p><p>Dr. Watts' clinical practice focuses on BPH, endourology, and prostate cancer detection and ablation. She also offers image-guided focal ablation for localized prostate cancer. She has a particular interest in active surveillance of prostate cancer and incorporating imaging modalities, particularly MRI imaging, into the diagnosis and treatment of localized prostate cancer.</p><p>Dr. Watts has numerous peer-reviewed publications, written several book chapters and co-edited a textbook. She has presented both nationally and internationally at various conferences and with the AUA regarding her work on quality improvement in healthcare and active surveillance and focal ablation in prostate cancer. She is involved in several national and international committees and editorial boards, including the AUA Quality Improvement and Patient Safety Committee, the Prostate Cancer Active Surveillance Research Initiative Advisory Committee, and the Urology Times Editorial Board.</p>

Is Open Scheduling
On

Alexander I. Sankin

Submitted by Anonymous (not verified) on
Alexander I. Sankin
https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/6a135040-3a87-11ed-8158-59ecbd24247c.jpg
Provider
Faculty
Expert
First Name
Alexander
Last Name
Sankin
NPI
1982866570
Faculty ID
14891
Clinical Terms
Employment Status
Full Time
Patient Type
Adult
Department
einstein-dept-urology
Gender
Male
Email
asankin@montefiore.org
Phone
347-842-1700
Titles
Type
Academic
Department
Department of Urology
Department Link
Rank
Associate Professor
Tags
me-patientcare-cancer-research-immunotherapy
Type
Clinical
Title
Attending Physician
Tags
me-patientcare-cancer-research-therapeutics
Type
Clinical
Title
Associate Professor, Urology
Type
Administrative
Locations
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84154 40.84612)
Address Line 1
1250 Waters place
City
Bronx
State
NY
Zip
10461-2720
Location Title
Montefiore at 1250 Waters Place
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.839137 40.8526781)
Building
Tower 1
Room
PH
Address Line 1
Montefiore Medical Center
Address Line 3
1250 Waters Place
City
Bronx
State
NY
Zip
10461
Location Title
Montefiore Medical Center
Education and Trainings
Education Type Label
Medical Education
Education Institution
New York University School of Medicine
Education Type Label
Fellowship
Education Institution
Memorial Sloan Kettering Cancer Center
Education Type Label
Residency
Education Institution
SUNY Downstate
Professional Interests

<p>Dr. Sankin is an academic surgeon in the Department of Urology, at Montefiore Medical Center with a clinical focus on surgical approaches to the management of urologic malignancies of the upper urinary tract and bladder. His academic focus is divided between clinical and translational research studying emerging treatments and techniques central to the surgical care of patients with urologic cancers.&nbsp;</p>
<p>Dr. Sankin is the site-Principal Investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin speardeaded the development of a bladder cancer clinical trials program at Einstein.&nbsp;</p>
<p>His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therpeutic targets. &nbsp;</p>
<p>&nbsp;</p>

Research Areas
Bladder preserving treatment options in patients with high risk bladder cancer, development of new immunotherapies for bladder cancer.
Expert Tags
Areas of Expertise
Urological malignancies
Prostate
Testicular
Bladder Carcinoma
Expert Summary

<p>Dr. Sankin current research program focuses on the translational application of immune-oncology to the treatment of urologic cancer.</p>

CHAM Provider
Off
Professional Title
M.D.
Clinical Focus

Dr. Sankin's&nbsp;clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Selected Publications

<p align="left">Clark TW,&nbsp;Sankin A, Becske T, Nelson PK, Fox M.&nbsp;&nbsp;Stent-assisted Gugliemi detachable coil repair of wide-necked renal artery aneurysm using 3-D angiography.&nbsp;&nbsp;Vasc Endovascular Surg 2008 Jan; 41(6):528-32</p>
<p align="left">Tareen B,&nbsp;Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS.&nbsp;Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort<em>.</em>&nbsp;Urology.&nbsp;&nbsp;2009 Feb;73(2):351-4</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Laterality alone should not drive selection of candidates for hemi-ablative focal therapy.&nbsp;J Urol.&nbsp;&nbsp;2009 Mar;181(3):1082-9</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?&nbsp;&nbsp;BJU Int. 2009 Jul;104(2):195-9</p>
<p align="left">Marien T,&nbsp;Sankin A, Lepor H.&nbsp;&nbsp;Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;J Urol.&nbsp;&nbsp;2009 Apr;181(4):1817-22</p>
<p align="left">Sankin A, Tareen B, Lepor H.&nbsp;&nbsp;Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;Prostate Cancer Prostatic Dis.&nbsp;&nbsp;2009;12(2):204-8</p>
<p align="left">Mufarrij P,&nbsp;Sankin A, Godoy G, Lepor H.&nbsp;Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2010 Sep;76(3):689-92</p>
<p align="left">Sankin A, Cohen J, Wang H, Macchia RJ, Karanikolas N.&nbsp;&nbsp;Rate of renal cell carcinoma subtypes in different races.&nbsp;&nbsp;Int Braz J Urol.&nbsp;&nbsp;2011 Feb;37(1):29-32</p>
<p align="left">Sankin A, Sfakianos J, Schiff J, Sjoberg D, Coleman J.&nbsp;Assessing renal function following partial nephrectomy using renal nuclear scintigraphy and eGFR.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2012 Aug;80(2):343-6</p>
<p align="left">Ghavamian R, Hakimi AA, Williams SK, Kim PH, Chen L, Sfakianos JP, Keren-Paz GE,&nbsp;Sankin A,&nbsp;Ginzburg N, Coleman JA.&nbsp;&nbsp;Factors affecting proportional glomerular filtration rate following minimally invasive partial nephrectomy.&nbsp;&nbsp;J Endourology&nbsp;&nbsp;2013 Nov;27(11):1371-5</p>
<p align="left">Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ.&nbsp;&nbsp;The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.&nbsp;&nbsp;Cancer Medicine 2014 Dec;3(6):1485-92</p>
<p align="left">Mano R, Vertosick E,&nbsp;Sankin A,&nbsp;Chevinsky M, Larish Y, Jakubowski CD, Hotker AM, Sjoberg D, Akin O, Russo P.&nbsp;&nbsp;The clinical significance of indeterminate pulmonary nodules in patients with renal cell carcinoma.&nbsp;&nbsp;J Urol 2014 Mar;193(3):776-82</p>
<p align="left">Chevinsky M, Imnadze M,&nbsp;Sankin A, Winer A, Mano R, Jakubowski C, Mashni J, Sjoberg DD, Chen YB, Tickoo SK, Reuter VE, Hakimi AA, Russo P.&nbsp;Pathologic stage T3a significantly increases disease recurrence across all tumor sizes in renal cell carcinoma.&nbsp;J Urol 2015 Aug;194(2):310-5</p>
<p align="left">Hakimi AA, Tickoo S, Jacobsen A, Sarungbam J, Sfakianos J, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Chen YB,&nbsp;Sankin A,&nbsp;Mano R, Coleman JA, Russo P, Ogawa S, Sander C, Hsieh JJ, Reuter VE.&nbsp;TCEB1-mutated renal cell carcinoma: a distinct genomic and morphologic subtype.&nbsp;&nbsp;Mod Pathol 2015 June;28(6):845-53</p>
<p align="left">Sankin A,&nbsp;Hakimi AA, Hsieh JJ, Molina AM.&nbsp;&nbsp;Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.&nbsp;&nbsp;Front Oncol 2015 Apr 8;5:67</p>
<p align="left">Hakimi AA, Ostrovnaya I, Jacobsen A, Susztak K, Coleman JA, Russo P, Winer AG, Mano R,&nbsp;Sankin A, Motzer RJ, Voss MH, Offit K, Purdue M, Pomerantz M, Freedman M, Choueiri TK, Hsieh JJ, Klein RJ.&nbsp;&nbsp;Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell&nbsp;carcinoma.&nbsp;&nbsp;Cancer 2016 Feb 1;122(3):402-10</p>
<p align="left">Sankin A. Discovering biomarkers within the genomic landscape of renal cell carcinoma.&nbsp;&nbsp;J Kidney 2016 Feb 2(1)&nbsp;</p>
<p align="left">Sankin A, Tin A, Mano R, Chevinsky M, Jakubowski C, Cha E, Yee A, Friedman F, Sjoberg D, Ehdaie B, Coleman J.&nbsp;&nbsp;Impact of ureteroscopy prior to nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes.&nbsp;&nbsp;Urology 2016 Aug; 94:148-53</p>
<p align="left">Mano R, Hakimi AA,&nbsp;Sankin AI,&nbsp;Sternberg IA, Chevinsky MS, Russo P.&nbsp;&nbsp;Surgical treatment of tumors involving kidneys with fusion anomalies &ndash; a contemporary series.&nbsp;&nbsp;Urology 2016 Aug; 98:97-102</p>
<p align="left">Zhou TC,&nbsp;Sankin A,&nbsp;Porcelli SA, Perlin DS, Schoenberg MP, Zang XX.&nbsp;&nbsp;A review of the PD-1/PD-L1 checkpoint in bladder cancer: from mediator of immune escape, to target for treatment.&nbsp;&nbsp;Urol Oncol 2017 Jan;35(1):14-20&nbsp;</p>
<p align="left">Winer AG, Vertosick EA, Ghanaat M, Corradi RB, Carlsson S, Sjoberg DD,&nbsp;Sankin AI,&nbsp;Sfakianos JP, Cha EK, Dalbagni G, Coleman JA.&nbsp;Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma.&nbsp;&nbsp;Urol Oncol 2017 April;35(4):151</p>
<p align="left">Sankin&nbsp;A,&nbsp;Narasimhulu&nbsp;D, John P,&nbsp;Gartrell&nbsp;B, Schoenberg M, Zang XX.&nbsp; The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: what lies beneath the tip of the iceberg, PD-L1.&nbsp;&nbsp;Urol&nbsp;Onc&nbsp;2017 (Epub ahead of print)</p>
<p align="left">Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T,&nbsp;Sankin A,&nbsp;Pierorazio PM, Schoenberg MP, Bivalacqua TJ. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer.&nbsp;&nbsp;Bladder Cancer 2017 Oct 27;3(4):293-303</p>
<p align="left">Daneshmand S, Patel s, Lotan Y, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O&rsquo;Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS,&nbsp;Flexible Blue Light Study Group Collaborators.&nbsp;Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.&nbsp;&nbsp;J Urol 2018 May;199(5):1158-65</p>
<p align="left">Fridman D, Abeshouse M,&nbsp;Sankin A.&nbsp;Paraurethral Leiomyoma as an Incidental Finding in a Patient with Fibroid Uterus. Case Rep Obstet Gynecol 2018 Feb 7;2018</p>
<p align="left">Adrianzen Hererra DA, Goldberg-Stein S,&nbsp;Sankin A, Sarungbam J, Sharma J, Gartrell BA. Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent Malignancies. Front Oncol, 2018 Apr 30;8:137</p>
<p align="left">Berstein A, Fram EB,&nbsp;Sankin A, Kovac E, Srivastava A, DiVito J, Stern JM. A Comparison of Perinephric Fat Surface Area and Mayo Adhesive Probability Score in Predicting Malignancy in T1 Renal Masses.&nbsp;&nbsp;Urol Onc 2018 Nov; 36(11):499</p>
<p align="left">Sun Y, Reuter VE, Magi-Galluzzi C,&nbsp;Sankin A,&nbsp;Epstein JI.&nbsp;Granular Cell Tumor of the Bladder: A Report of Six Cases.&nbsp;&nbsp;Urology 2018 Nov; 121:203&nbsp;</p>
<p align="left">Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ,&nbsp;Sankin A,&nbsp;Schoenberg MP, Shipley WU, Villers A, Efstathiou J, Bellmunt J, Stenzl A.&nbsp;&nbsp;Recommendations From Joint SIU-ICUD Consultation On Bladder Cancer: Muscle-Invasive Presumably Regional Tumor.&nbsp;&nbsp;World J Urol 2019, Jan;37(1): 61-83</p>
<p align="left">Chand D, Dhawan D,&nbsp;Sankin A, Ren X, Lin J, Schoenberg M, Knapp DW, Zang X. Immune checkpoint B7x (B7-H4/B7S1/VtCN1) is overexpressed in spontaneous canine bladder cancer: the first report and its implications in a preclinical model. Bladder Cancer 2019, Jan 31;5(1)63-71</p>
<p align="left">Bernstein A, Barry E, Fram EB,&nbsp;Sankin A,&nbsp;Kovac E, Stern JM.&nbsp;Does Glomerular Filtration Rate at Discharge After Partial Nephrectomy Predict Long-Term Glomwerular Filtration Rate Stability?. J Endourol 2019, Jun;33(6):488-491</p>
<p align="left">Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat A, Konety B, Malmstrom PU, McKiernan J, O&rsquo;Donnell M, Patel S, Pohar K, Resnick M,&nbsp;Sankin A,&nbsp;Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.&nbsp;&nbsp;Blue light flexible cystoscopy with hexaminolevulinate in non-muscle invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA &ndash; update 2018. Nat Rev Urol 2019, Jun;16(6):377-386</p>
<p align="left">Sankin A,&nbsp;Chand D, Schoenberg M, Zang X.&nbsp;&nbsp;Human urothelial bladder cancer generates a clonal immune response: the results of T-cell receptor sequencing.&nbsp;&nbsp;Urol Oncol 2019, May 15 (epub ahead of print).</p>
<p align="left">Wang H, Kaur G,&nbsp;Sankin A,&nbsp;Chen F, Guan F, Zang X.&nbsp;Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.&nbsp;&nbsp;J Hematol Oncol 2019, Jun 11;12(1):59</p>
<p align="left">Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ,&nbsp;Sankin A, Kates M.&nbsp;&nbsp;Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urol Oncol 2019, Jun 26 (epub ahead of print)</p>
<p align="left">Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ,&nbsp;Sankin A, Kates M. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle invasive bladder cancer.&nbsp;&nbsp;Urol Oncol 2019, Aug 28 (epub ahead of print)</p>
<p align="left">Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Holmes CJ, Shreck E, Assi H, Gartrell BA, Sankin A,&nbsp;Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P.&nbsp;&nbsp;Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors.&nbsp;&nbsp;Cancer 2019, Dec 12 (epub ahead of print)</p>

EMR ID
78143
Biography

<p>Alexander I. Sankin, MD, is Associate Professor, Urology at Montefiore Einstein. His clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.</p><p>After earning his Master of Science from the University of Pennsylvania in 2004, Dr. Sankin earned his Doctor of Medicine from New York University in 2008 and completed his residency in surgery and urology at the State University of New York Downstate in 2013. He then completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in 2015.</p><p>Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer. He is the site-principal investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums, including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin spearheaded the development of a bladder cancer clinical trials program at Einstein. His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therapeutic targets. His work has been published in numerous peer-reviewed journals.</p><p>Dr. Sankin is board certified and a member of the American Urological Association and the Society of Urologic Oncology.</p>

Is Open Scheduling
Off

Shalom Kalnicki

Submitted by Anonymous (not verified) on
Shalom Kalnicki
https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/89820450-b883-11ee-8618-fda8dc77c52b.jpg
Provider
Faculty
Expert
First Name
Shalom
Last Name
Kalnicki
NPI
1942381371
Faculty ID
9551
Employment Status
Full Time
Patient Type
Adult
Department
einstein-dept-radiation-oncology
einstein-dept-urology
Gender
Male
Email
skalnick@montefiore.org
Phone
718-920-5280
Titles
Type
Academic
Department
Department of Radiation Oncology
Rank
Professor
Type
Academic
Department
Department of Urology
Department Link
Rank
Professor
Type
Clinical
Title
Associate Director, Clinical Affairs, Montefiore Einstein Comprehensive Cancer Center
Tags
me-patientcare-cancer-about-associate-directors
me-patientcare-cancer-clinical-lung
me-patientcare-cancer-clinical-head-neck
me-patientcare-cancer-clinical-thyroid
me-patientcare-cancer-research-therapeutics
Type
Administrative
Title
Chair, Department of Radiation Oncology
Tags
me-neuroscience-skullcranialbasecenterteam
Type
Administrative
Title
Associate Director, Clinical Affairs, Montefiore Einstein Comprehensive Cancer Center
Locations
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84607 40.84531)
Address Line 1
1521 Jarrett Place
City
Bronx
State
NY
Zip
10461-2606
Location Title
Montefiore M-E Center for Cancer Care
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.89216 40.85293)
Address Line 1
4487 Third Avenue
City
Bronx
State
NY
Zip
10457-1526
Location Title
Montefiore at St. Barnabas
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.86782 41.01564)
Address Line 1
18 Ashford Avenue
City
Dobbs Ferry
State
NY
Zip
10522-1823
Location Title
Montefiore Dobbs Ferry Practice
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84599 40.84617)
Address Line 1
1625 Poplar Street
City
Bronx
State
NY
Zip
10461-2653
Location Title
Montefiore Medical Park at 1625 Poplar
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84154 40.84612)
Address Line 1
1250 Waters Place
City
Bronx
State
NY
Zip
10461-2720
Location Title
Montefiore at 1250 Waters Place
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.8608 40.89439)
Address Line 1
600 East 233rd Street
City
Bronx
State
NY
Zip
10466-2604
Location Title
Montefiore Wakefield Campus
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.78729 40.91321)
Address Line 1
16 Guion Place
City
New Rochelle
State
NY
Zip
10801-5502
Location Title
Montefiore New Rochelle Hospital
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.89112 40.85373)
Address Line 1
4422 Third Avenue
City
Bronx
State
NY
Zip
10457-2594
Location Title
St. Barnabas Hospital
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.88072 40.88002)
Address Line 1
111 East 210th Street
City
Bronx
State
NY
Zip
10467-2401
Location Title
Montefiore Medical Center
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.8459036 40.846387)
Address Line 1
Montefiore Medical Group
Address Line 3
1625 Poplar Street
City
Bronx
State
NY
Zip
10461
Location Title
Montefiore Medical Group
Education and Trainings
Education Type Label
Medical Education
Education Institution
University of Sao Paulo
Education Type Label
Fellowship
Education Institution
Montefiore Medical Center
Education Type Label
Residency
Education Institution
Montefiore Medical Center
Professional Interests

<p>Dr. Kalnicki, a radiation oncologist, focuses on new technologies in the radiation treatment of cancer. He was a pioneer in the use of intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), target motion management with 4-D radiation planning, and functional tumor imaging with PET-CT (positron emission tomography &ndash; CAT scan) fusion techniques. Another area of interest is the use of stereotactic guidance in radiation treatment, specifically for stereotactic radiosurgery (SRS). All enhance precision of tumor targeting with radiation therapy, increasing dose to the tumor, while sparing surrounding normal tissues.<br />&nbsp;<br />Dr. Kalnicki's research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies. His clinical interests focus on head and neck, prostate, and breast cancers.</p>

Specialties
Expert Tags
Areas of Expertise
IMRT
IGRT
Tumor imaging with PET/CT fusion techniques
Radiation therapy for head and neck cancers prostate cancer, and breast cancer
Expert Summary

<p>Dr. Kalnicki focuses on researching and implementing new technologies in the radiation treatment of cancer, with the aim of enhancing the dose to the tumor target while preserving normal tissues from radiation injury, potentially increasing tumor control and improving quality of life. His research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies.</p>

CHAM Provider
Off
Professional Title
M.D.
Clinical Focus

Radiation Oncology

Research Focus

An active researcher, Dr. Kalnicki is currently investigating innovative methods of radiation planning and delivery, including Intensity Modulated Radiation Therapy (IMRT), PET-CT fusion for radiation planning, 4-D treatment planning, target motion manage

EMR ID
4214
Biography

<p>Dr. Kalnicki focuses on researching and implementing new technologies in the radiation treatment of cancer, with the aim of enhancing the dose to the tumor target while preserving normal tissues from radiation injury, potentially increasing tumor control and improving quality of life. He pioneered the use of intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), target motion management with 4-D radiation planning, stereotactic body radiation therapy (SBRT) and functional tumor imaging with PET-CT (positron emission tomography &ndash; CAT scan) fusion techniques. His research has implications for radiation treatment planning and techniques used for most clinical situations in radiation oncology, including brain, head and neck, thoracic, upper abdominal and pelvic malignancies.</p><p>Dr. Kalnicki earned his medical degree at the University of Sao Paulo Medical School in Sao Paulo, Brazil. He completed his residency and fellowship in radiotherapy at Montefiore and Albert Einstein College of Medicine. He came to Montefiore and Einstein from the University of Pittsburgh, School of Medicine, where he was Vice Chairman for Clinical Affairs and Director of Radiation Oncology at the University of Pittsburgh Cancer Institute. </p><p>Prior to joining the University of Pittsburgh Cancer Institute, Dr. Kalnicki served as Chairman of the Department of Radiation Oncology at Allegheny University of Health Sciences in Pittsburgh. He is a member of many prominent professional societies. He has authored numerous articles and abstracts during his career and is a recipient of several awards, including the Fellowship Award from the American College of Radiation Oncology.</p>

Is Open Scheduling
Off

Hilda Haynes-Lewis

Submitted by Anonymous (not verified) on
Hilda Haynes-Lewis
https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/e7712260-3933-11ed-9b41-f32856b0701a.jpg
Provider
Faculty
First Name
Hilda
Last Name
Haynes-Lewis
NPI
1306927736
Faculty ID
15628
Employment Status
Full Time
Patient Type
Adult
Department
einstein-dept-radiation-oncology
Gender
Female
Email
hhaynes@montefiore.org
Phone
718-920-7750
Titles
Type
Academic
Department
Department of Radiation Oncology
Rank
Assistant Professor
Type
Administrative
Locations
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.86782 41.01564)
Address Line 1
18 Ashford Avenue
City
Dobbs Ferry
State
NY
Zip
10522-1823
Location Title
Montefiore Dobbs Ferry Practice
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.89216 40.85293)
Address Line 1
4487 Third Avenue
City
Bronx
State
NY
Zip
10457-1526
Location Title
Montefiore at St. Barnabas
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84599 40.84617)
Address Line 1
1625 Poplar Street
City
Bronx
State
NY
Zip
10462-2653
Location Title
Montefiore Medical Park at 1625 Poplar
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.88072 40.88002)
Address Line 1
111 East 210th Street
City
Bronx
State
NY
Zip
10461-2401
Location Title
Montefiore Medical Center
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84607 40.84531)
Address Line 1
1521 jarrett Place
City
Bronx
State
NY
Zip
10461-2606
Location Title
Montefiore M-E Center for Cancer Care
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.92481 41.09677)
Address Line 1
160 North Midland Avenue
City
Nyack
State
NY
Zip
10960-1912
Location Title
Montefiore Nyack Hospital
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.92749 41.09467)
Address Line 1
111 North Highland Avenue
City
Nyack
State
NY
Zip
10960
Location Title
Montefiore Einstein Radiation Oncology at North Highland
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.91189 40.82636)
Address Line 1
951 Brook Avenue
City
Bronx
State
NY
Zip
10451
Location Title
Montefiore at 951 Brook Avenue
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.8798833 40.8799447)
Building
Rosenthal Pavilion
Room
100
Address Line 1
Montefiore Medical Center
Address Line 3
111 East 210th Street
City
Bronx
State
NY
Zip
10467
Location Title
Montefiore Medical Center
Education and Trainings
Education Type Label
Medical Education
Education Institution
Columbia University
Education Type Label
Medical Education
Education Institution
University Of Utah
CHAM Provider
Off
Professional Title
Ph.D.
Clinical Type
Nurse Practitioner
EMR ID
9852
Is Open Scheduling
Off

Benjamin A. Gartrell

Submitted by Anonymous (not verified) on
Benjamin A. Gartrell
https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c70fa690-d525-11eb-9d97-7bd8ea6b93dc.jpg
Provider
Faculty
First Name
Benjamin
Last Name
Gartrell
NPI
1043414451
Faculty ID
13485
Employment Status
Full Time
Patient Type
Adult
Department
einstein-dept-oncology
einstein-dept-medicine
einstein-dept-urology
Gender
Male
Email
bgartrel@montefiore.org
Phone
718-405-8404
Titles
Type
Academic
Department
Department of Oncology
Rank
Associate Professor
Tags
me-patientcare-cancer-clinical-genitourinary-urologic
me-patientcare-cancer-research-therapeutics
Division
Medical Oncology
Type
Academic
Department
Department of Medicine
Department Link
Rank
Associate Professor
Division
Oncology & Hematology
Type
Academic
Department
Department of Urology
Department Link
Rank
Associate Professor
Type
Administrative
Locations
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84475 40.84623)
Address Line 1
1695 Eastchester Road
City
Bronx
State
NY
Zip
10461
Location Title
Montefiore Medical Park at Eastchester
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.88072 40.88002)
Address Line 1
111 East 210th Street
City
Bronx
State
NY
Zip
10461-2401
Location Title
Montefiore Medical Center
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84563 40.84596)
Address Line 1
1575 Blondell Avenue
City
Bronx
State
NY
Zip
10461-2601
Location Title
Montefiore Medical Park at 1575 Blondell
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.845166 40.8462736)
Room
244
Address Line 1
Montefiore Medical Park
Address Line 3
1695 Eastchester Road
City
Bronx
State
NY
Zip
10461
Location Title
Montefiore Medical Park
Education and Trainings
Education Type Label
Medical Education
Education Institution
Feinberg School of Medicine, Northwestern University
Education Type Label
Fellowship
Education Institution
Mount Sinai Hospital
Education Type Label
Residency
Education Institution
University Hospitals Case Medical Center
CHAM Provider
Off
Professional Title
M.D.
Clinical Focus

Dr. Gartrell's clinical focus has been on treating genitourinary malignancies including prostate cancer, bladder cancer, renal cell cancer, and testicular cancer.&nbsp;

Research Focus

With a vast range of research interests, Dr. Gartrell focuses on translational research evaluating the significance of a novel immune checkpoint molecule in bladder cancer, evaluating the role of the autonomic nervous system in prostate cancer, toxicities associated with anticancer therapies, and the impact of bone metastasis on patients with prostate cancer.&nbsp;

EMR ID
5599
Biography

<p>Benjamin A. Gartrell, MD, is Director, Genitourinary Malignancy Program at Montefiore and an Assistant Professor of Oncology and Urology at our Albert Einstein College of Medicine. Since joining the Montefiore team in 2012, his expertise has been in treating genitourinary malignancies including prostate cancer, bladder cancer, renal cell cancer, and testicular cancer. He is also very active in translating science findings in collaboration with research colleagues at Einstein. </p><p>In 2000, Dr. Gartrell received his Bachelor of Arts in Chemistry at the College of Wooster in Ohio. Following this, he attended the Northwestern University?s Feinberg School of Medicine, in Chicago, Illinois, where he received his Doctor of Medicine in 2005. His postgraduate training began in 2005 with an internship and residency in Internal Medicine at Case Western Reserve University, which he completed in 2008. He then completed a fellowship in Hematology/Oncology at Mount Sinai School of Medicine in 2012 and became Chief Fellow from 2010-2011. </p><p>With a vast range of research interests, Dr. Gartrell focuses on translational research evaluating the significance of a novel immune checkpoint molecule in bladder cancer, evaluating the role of the autonomic nervous system in?prostate cancer, toxicities associated with anticancer therapies, and the impact of bone metastasis on patients with prostate cancer. His work has been published in a number of peer-reviewed journals, including the Journal of Clinical Oncology, Urologic Oncology, and European Urology. Dr. Gartrell also participates in community outreach to promote Prostate Cancer Awareness.</p><p>In 2015, Dr. Gartrell received Most Outstanding Faculty Educator, selected by the graduating oncology fellows at our Albert Einstein College of Medicine. He is also a recipient of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO). He is board certified by the American Board of Internal Medicine in Medical Oncology and Hematology, and is a member of the American Society of Clinical Oncology. </p>

Is Open Scheduling
Off

Anna C. Ferrari

Submitted by Anonymous (not verified) on
Anna C. Ferrari
https://assets.montefioreeinstein.org/profiles/images/physphoto/Ferrari_Anna_MD_420x504.jpg
Provider
Faculty
First Name
Anna
Last Name
Ferrari
NPI
1316948268
Faculty ID
16250
Clinical Terms
Employment Status
part-time
Patient Type
Adult
Department
einstein-dept-oncology
einstein-dept-medicine
Gender
Female
Email
aferrari@montefiore.org
Phone
718-405-8505
Titles
Type
Academic
Department
Department of Oncology
Rank
Professor
Division
Medical Oncology
Type
Academic
Department
Department of Medicine
Department Link
Rank
Professor
Division
Oncology & Hematology
Type
Administrative
Locations
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84475 40.84623)
Address Line 1
1695 Eastchester Road
City
Bronx
State
NY
Zip
10461
Location Title
Montefiore Medical Park at Eastchester
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.845166 40.8462736)
Address Line 1
Montefiore Medical Park
Address Line 3
1695 Eastchester Road
City
Bronx
State
NY
Zip
10461
Location Title
Montefiore Medical Park
Education and Trainings
Education Type Label
Medical Education
Education Institution
Fac De Med De La Univ of La Republica, Uruguay
Education Type Label
Fellowship
Education Institution
Bellevue Hospital
Education Type Label
Fellowship
Education Institution
North Central Bronx Hospital
Education Type Label
Fellowship
Education Institution
University of Maryland Medical Center
Education Type Label
Residency
Education Institution
Union Memorial Hospital
CHAM Provider
Off
Professional Title
M.D.
EMR ID
114467
Is Open Scheduling
Off

Ahmed Aboumohamed

Submitted by Anonymous (not verified) on
Ahmed Aboumohamed
https://assets.montefioreeinstein.org/profiles/images/Aboumohamed_Ahmed_MD_2x.jpg
Provider
Faculty
First Name
Ahmed
Last Name
Aboumohamed
NPI
1679842835
Faculty ID
15520
Clinical Terms
Employment Status
Full Time
Patient Type
Adult
Department
einstein-dept-urology
Gender
Male
Email
aaboumoh@montefiore.org
Phone
347-842-1700
Titles
Type
Academic
Department
Department of Urology
Department Link
Rank
Professor
Type
Clinical
Title
Director, Robotic and Minimally Invasive Urologic Surgery
Tags
me-patientcare-urology-urologiconcology
Type
Clinical
Title
Professor, Urology
Type
Clinical
Type
Clinical
Type
Administrative
Locations
Is Primary
On
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.87862 40.88032)
Address Line 1
3400 Bainbridge Avenue
City
Bronx
State
NY
Zip
10467-240
Location Title
Montefiore Greene Medical Arts Pavilion
Is Primary
Off
Type
Clinical
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.84154 40.84612)
Address Line 1
1250 Waters place
City
Bronx
State
NY
Zip
10461-2720
Location Title
Montefiore at 1250 Waters Place
Is Primary
Off
Type
Academic
Location (Address, State, City, Zip)
Not used, will be deleted
Coordinates
POINT (-73.839137 40.8526781)
Building
Tower 1
Room
2
Address Line 1
Montefiore Medical Center
Address Line 3
1250 Waters Place
City
Bronx
State
NY
Zip
10461
Location Title
Montefiore Medical Center
Education and Trainings
Education Type Label
Medical Education
Education Institution
Cairo University
Education Type Label
Fellowship
Education Institution
Wake Forest Medical Center
Education Type Label
Fellowship
Education Institution
Roswell Park Cancer Institute
Education Type Label
Fellowship
Education Institution
Montefiore Medical Center
Education Type Label
Fellowship
Education Institution
Cleveland Clinic
Education Type Label
Residency
Education Institution
Cairo University Hospital
Professional Interests

<p style="margin-top: 0px; margin-bottom: 1em; padding-top: 0px; color: #525458; font-family: Arial, Helvetica, sans-serif; font-size: 12px;">Ahmed Aboumohamed, MD is an Attending Physician and an Associate Professor in the Department of Urology at Montefiore and our Albert Einstein College of Medicine. Dr. Aboumohamed's areas of expertise include urology, urologic oncology, minimally invasive and robotic surgery, and urologic reconstruction.</p>
<p style="margin-top: 0px; margin-bottom: 1em; padding-top: 0px; color: #525458; font-family: Arial, Helvetica, sans-serif; font-size: 12px;">Dr. Aboumohamed's research includes minimally invasive and robotic surgery for urologic malignancies. He has numerous publications including peer-reviewed articles and book chapters. His research has been published in multiple peer-reviewed journals including Journal of Urology, British Journal of Urology International, and Urology Gold Journal.</p>

Research Areas
Management of high risk prostate cancer, Minimally Invasive approaches for management of different urologic cancers, Microbiome and its relationship to prostate and bladder cancer.
CHAM Provider
Off
Professional Title
M.B.,B.Ch.
Clinical Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Dr. Aboumohamed's areas of expertise include urology, urologic oncology, minimally invasive and robotic surgery, and urologic reconstruction.</span><quillbot-extension-portal></quillbot-extension-portal>

Research Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Dr. Aboumohamed's research includes minimally invasive and robotic surgery for urologic malignancies, and the treatment of complex urethral reconstruction.&nbsp;</span><quillbot-extension-portal></quillbot-extension-portal>

Selected Publications

<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">K. Mursi, M.G. El-Sheikh, H. AbdelRaouf, </span><span style="font-size: 12.0pt; mso-bidi-font-weight: normal; mso-bidi-font-style: normal;">A.A. Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">, Y. Ramadan, A. Lotfi. <u>Evaluating the need for transurethral bladder biopsy at first follow up after intravesical BCG therapy for superficial bladder cancer: Preliminary data.</u> African Journal of Urology 2012; 18(1),16-19.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">2.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt;">Ahmed Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-weight: bold;"> and Daniel A Shoskes.</span> <u><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-weight: bold;">A Simple, Algorithmic and Effective Approach to Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome.</span></u><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-weight: bold;"> Timely Top Med Uro Int. 2013; Vol. 15; 7-91521.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">3.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt;">Aboumohamed A</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-weight: bold;">, Mosaad S, Srinivas T, Chiesa-Vottero A, Flechner S. <u>Disseminated Adenoviral Infection Masquerading as Lower Urinary Tract Voiding Dysfunction in a Kidney Transplant Recipient.</u> Clin Nephrol. 2014;82(5):332-6.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">4.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt;">Ahmed A. Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-weight: bold;"> and Khurshid Guru. <u>Robot-Assisted Radical Prostatectomy: Getting your ducks in a row!</u> BJU Int 2013; 111(4):528-9.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">5.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">Ali Al-Daghmin, </span><span style="font-size: 12.0pt; mso-bidi-font-weight: normal; mso-bidi-font-style: normal;">Ahmed Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">, Rakeeba Din, Diana Mehedint, Yi Shi,<span style="mso-spacerun: yes;">&nbsp;&nbsp;&nbsp; </span>Gregory Wilding, Khurshid Guru. <u>Readmission Following Robot-assisted Radical<span style="mso-spacerun: yes;">&nbsp;&nbsp; </span>Cystectomy: Outcomes and Predictors at 90 days.</u> Urology 2014;83(2):350-6.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">6.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">Michael Hanzly, </span><span style="font-size: 12.0pt; mso-bidi-font-weight: normal; mso-bidi-font-style: normal;">Ahmed Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">, Naveen Yarlagadda, Lorenzo Digiorgio, Ariel Fredrick, Gaurav Rao, Diana Mehedint, Kristopher Attwood, Eric Kauffman, Deepika Narashima, Saby George, Nikhil Khushilani, Roberto Pili, Thomas Schwaab. <u>High-Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma: a Contemporary Experience.</u> Urology 2014; 83(5):1129&ndash;1134.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">7.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt;">Ahmed Aboumohamed, </span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-weight: bold;">Christopher Tallman, Alon Weizer, Heather Crossley,<span style="mso-spacerun: yes;">&nbsp;&nbsp; </span>Stephen Dailey, Aabroo Khan, Rakeeba Din, Diana Mehedint, Yi Shi, Terry Creighton, Mohamed Sharif, Gregory Wilding, Khurshid A.Guru. <u>Health-related Quality of Life Outcomes after Robot-assisted and Open Radical Cystectomy: a multi-institutional Study.</u> Urology 2014;83(6):1300-8.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">8.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt;">Ahmed A. Aboumohamed, </span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-weight: bold;">Robert C Covell, and Ashok Hemal. <u>Robot-assisted laparoscopic repair of vesicvaginal fistula.</u> AUA News; January 2015; volume 20, issue 1.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">9.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt;">Ahmed A. Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-weight: bold;">, and Ashok Hemal. <u>Should Post-kidney Transplant Patients with Localized Prostate Cancer be undergoing Robotic Radical Prostatectomy?</u> Int Urol Nephrol. 2015; 47(4):643-4.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">10.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-weight: bold;">Manish Patel, </span><span style="font-size: 12.0pt;">Ahmed A. Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-weight: bold;">, and Ashok Hemal. <u>Does transition from daVinci Si to daVinci Xi robotic platform impact single-docking technique for robot-assisted laparoscopic nephroureterectomy?</u> BJU Int. 2015 Dec;116 (6): 990-4.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">11.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt;">Ahmed A. Aboumohamed, </span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-weight: bold;">L Spencer Krane, and</span> <span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-weight: bold;">Ashok K. Hemal. <u>Oncologic outcomes following<span style="mso-spacerun: yes;">&nbsp;&nbsp; </span>robot-assisted laparoscopic nephroureterectomy with bladder cuff excision for upper tract urothelial Carcinoma.</u> J Urol. 2015 Dec;194(6):1561-6.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">12.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt;">Ahmed Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-weight: bold;">. <u>Imaging for Small renal masses</u>. Egyptian Journal of Urology. Nov 2016.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">13.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">Nyame YA, Babbar P, </span><span style="font-size: 12.0pt; mso-bidi-font-weight: normal; mso-bidi-font-style: normal;">Aboumohamed AA</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">, Mori RL, Flechner SM, Modlin CS. <u>Ex-vivo partial nephrectomy after living donor nephrectomy: Surgical technique for expanding kidney donor pool</u>. Urol Ann. 2017 Jan-Mar;9(1):107-109. doi: 10.4103/0974-7796.198913.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">14.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">Lin W, Watts K, </span><span style="font-size: 12.0pt; mso-bidi-font-style: normal;">Aboumohamed A</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">. <u>Renoalimentary fistula: Case report of a renoduodenal fistula and systematic literature review</u>. Urol Case Rep. 2018 Mar 2;18:41-43. doi: 10.1016/j.eucr.2018.02.022.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">15.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">J. Tam, K. Plewniak, </span><span style="font-size: 12.0pt; mso-bidi-font-style: normal;">A. Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">, J. Shin. <u>Surgical Management of Deep Infiltrating Bladder Endometriosis with Rare Pathological Findings</u>. Journal of Minimally Invasive Gynecology. Nov 2018. Doi: 10.2016/j.jmig.2018.09.660</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">16.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; mso-fareast-font-family: 'Arial Unicode MS'; color: #222222; font-weight: normal;">Meenakshi Davuluri, Bronwyn Long, Stacia Semple, Esperanza Villanueva-Siles, </span><span style="font-size: 12.0pt; mso-fareast-font-family: 'Arial Unicode MS'; color: #222222;">Ahmed Aboumohamed.</span> <span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">Primary Urethral Melanoma: a case reports and brief literature review. Urology. 2018 Dec 31. doi: 10.1016/j.urology.2018.12.027.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">17.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">Lin W, Davuluri M, Watts K, </span><span style="font-size: 12.0pt; mso-bidi-font-style: normal;">Aboumohamed A</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">. <u>Non-familial Synchronous Bilateral Renal Cell Carcinoma with Bilateral Synchronous Renal Vein Extension and Inferior Vena Cava Thrombus</u>. Curr Urol. 2019 Sep; 13(1): 51&ndash;53.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">18.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">Emily Barry, Ilir Agalliu, Richard Maiman, Evan Shreck, Evan Kovac, </span><span style="font-size: 12.0pt; mso-bidi-font-style: normal;">Ahmed Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">, Alexander Sankin. <u>Outcomes of Intravesical Bacillus Calmette-Guerin in a Multiracial Cohort with Non-muscle Invasive Bladder cancer</u>. Urology Practice; April 2020, doi:10.1097/UPJ.0000000000000154</span><em><span style="font-size: 12.0pt; font-weight: normal;">.</span></em></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">19.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">Hussein AA,&hellip; </span><span style="font-size: 12.0pt; mso-bidi-font-style: normal;">Ahmed Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">,&hellip;Mani Menon, Khurshid Guru. <u>A comparative propensity score-matched analysis of perioperative outcomes of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.</u> BJU Int. 2020 Aug;126(2):265-272. doi: 10.1111/bju.15083.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">20.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">Kara L Watts, Laena Frechette, Ben Muller, Dan Ilinksy, Evan Kovac, Alex Sankin, and </span><span style="font-size: 12.0pt; mso-bidi-font-weight: normal; mso-bidi-font-style: normal;">Ahmed Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">. <u>Systematic review and meta-analysis comparing cognitive vs. image-guided fusion prostate biopsy for the detection of prostate cancer</u>. Urol Oncol. 2020 Sep;38(9):734.e19-734.e25.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">21.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; mso-bidi-font-weight: normal; mso-bidi-font-style: normal;">Ahmed Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">, Josh Gottlieb, Matthew DeMasi, Emily Barria, Alexander Sankin, and Kara Watts. <u>Methodology for the Triage of Urologic Surgical Cases in the Setting of a Pandemic.</u> BMC Surg, 2021 Mar 6;21(1):116. doi: 10.1186/s12893-021-01067-9</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">22.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">Ari Bernstein, Matthew DeMasi, Meenakshi Davuluri, Alexander Sankin, Maria Ajaimy, Jay Graham, Judy Sarungbam, </span><span style="font-size: 12.0pt; mso-bidi-font-weight: normal; mso-bidi-font-style: normal;">Ahmed Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">, Kara Watts, Joshua Stern, Evan Kovac. <u>Native Kidney Small Renal Masses in Patients with Kidney Transplants. Is Surveillance Safe in the Immunosuppressed?</u> Can Urol Assoc J 2021 Mar 18. doi: 10.5489/cuaj.6996. Online ahead of print.</span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">23.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">Joseph I. Kim, Denzel Zhu, Emily Barry, Evan Kovac, </span><span style="font-size: 12.0pt; mso-bidi-font-weight: normal; mso-bidi-font-style: normal;">Ahmed Aboumohamed,</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"> Ilir Agalliu, Alexander Sankin. <u>Intravesical BCG treatment is inversely associated with the risk of developing Alzheimer&rsquo;s Disease or other dementia among non-muscle-invasive bladder cancer patients.</u> Accepted for Publication - Clinical Gen Urinary Cancer. <u></u></span></p>
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">24.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">Ritesh Aggarwal, Yiyu Zou, Rebecca Luchtel, Kith Pradhan, Nadia Ashai, Nandini Ramachandra, Joseph Albanese, Jung-in Yang, Xiaoyang Wang, Srinivas Aluri, Shanisha Gordon, Venkata Machha, Alexander Tischer, </span><span style="font-size: 12.0pt; mso-bidi-font-weight: normal; mso-bidi-font-style: normal;">Ahmed Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">, Benjamin Gartrell, Sassan Hafizi, James Pullman, Niraj Shenoy. <u>Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer</u>. Accepted <em style="mso-bidi-font-style: normal;">in press</em> - Proc Natl Acad Sci U S A doi: <a href="https://doi.org/10.1101/2020.07.05.188433">https://doi.org/10.1101/2020…;
<p class="MsoNormal" style="margin-left: .75in; text-align: justify; text-indent: -.25in; mso-list: l0 level2 lfo1; tab-stops: 0in 31.5pt 49.5pt;"><!-- [if !supportLists]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;"><span style="mso-list: Ignore;">25.<span style="font: 7.0pt 'Times New Roman';">&nbsp; </span></span></span><!--[endif]--><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">Justin Loloi, Evan Kovac, </span><span style="font-size: 12.0pt; mso-bidi-font-weight: normal; mso-bidi-font-style: normal;">Ahmed Aboumohamed</span><span style="font-size: 12.0pt; font-weight: normal; mso-bidi-font-style: normal;">. <u>Ureteral Metastasis in Colorectal Cancer: A Case Report and Review of Literature</u>. Accepted <em style="mso-bidi-font-style: normal;">in press. </em>Urology Case reports.</span></p>

EMR ID
76897
Biography

<p>Ahmed Aboumohamed, MD is an Attending Physician and a Professor in the Department of Urology at Montefiore and our Albert Einstein College of Medicine. Dr. Aboumohamed's areas of expertise include urology, urologic oncology, minimally invasive and robotic surgery, and urologic reconstruction.</p><p>Dr. Aboumohamed earned his medical degree, as well as clinical masters and clinical doctorate degrees in urology from Cairo University School of Medicine. He completed his medical internship and urology residency at Cairo University. He was subsequently appointed as a faculty member at Cairo University. Additionally, he was a fellow at Cleveland Clinic; Roswell Park Cancer Institute; Wake Forest University Baptist Medical Center; and Montefiore.</p><p>Dr. Aboumohamed's research includes minimally invasive and robotic surgery for urologic malignancies, and the treatment of complex urethral reconstruction. He has numerous publications including peer-reviewed articles and book chapters. His research has been published in multiple peer-reviewed journals including Journal of Urology, British Journal of Urology International, and Urology Gold Journal.</p><p>He is a member of the European Association of Urology (EAU) and the American Urological Association (AUA).</p>

Is Open Scheduling
Off
Subscribe to Prostate Cancer